Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty‐Two–Week Phase III Randomized Study Results

OBJECTIVE: The 24‐week equivalent efficacy and comparable safety results of the biosimilar SB5 and reference adalimumab (ADA) from the phase III randomized study in patients with moderate‐to‐severe rheumatoid arthritis (RA) have been reported previously. We undertook this transition study to evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinblatt, Michael E., Baranauskaite, Asta, Dokoupilova, Eva, Zielinska, Agnieszka, Jaworski, Janusz, Racewicz, Artur, Pileckyte, Margarita, Jedrychowicz‐Rosiak, Krystyna, Baek, Inyoung, Ghil, Jeehoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001519/
https://www.ncbi.nlm.nih.gov/pubmed/29439289
http://dx.doi.org/10.1002/art.40444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001519/
https://www.ncbi.nlm.nih.gov/pubmed/29439289
http://dx.doi.org/10.1002/art.40444

Ejemplares similares